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Knowledge  of  the  number  of  cells  from  which  a  tumor  originates  can  provide 
important  information  about  its  etiology  and  pathogenesis.  For  example,  clonal 
origin would be expected from a rare and random oncogenic event, or even if multiple 
cells were affected  initially, but only one clone emerged to form the mature  tumor. 
The  problem  of  tumor  cell  origin can be approached  by  studying neoplasms  from 
patients with mosaicism of two or more cell types. Such mosaicism is regularly demon- 
strated in the cells of mammalian females due to random X  chromosome  inactivation 
in early  embryonic development. The  X-linked glucose-6-phosphate  dehydrogenase 
(G-6-PD) 1  locus is particularly useful as a marker. Thus, females who are heterozygous 
for  the  usual B  gene  (Gd  B)  at  the  G-6-PD locus and a  variant  allele such  as  Gd  A 
have two distinct cell types (1-3).  Gd  B is active in one population of cells, which con- 
sequently produces type B  enzyme; in the other population Gd  A is active, producing 
the variant A  type enzyme. Tumors with a  clonal origin in a  GdB/Gd  A  heterozygote 
should therefore contain either B  or A  type G-6-PD whereas those  with multicellular 
origin may exhibit both B and A types. 
Such studies of G-6-PD types when applied to Burkitt lymphoma adduced evidence 
that individual Burkitt tumors have clonal origins (4,  5). Limited studies  of multiple 
tumors  from  the  same  patients  suggested  that  the  entire  disease  is  clonal  (4,  5). 
In one patient, we found that an exacerbation after a  long-term remission  was  not 
due to reemergence of the originally detected malignant clone, but was probably the 
result of a  "new" induction of disease  (6).  As such suggestions have major implica- 
tions for  the  etiology and pathogenesis of  this malignancy, it is  important to  test 
their validity with additional cell markers. 
Another way of marking cells is to test them for surface-associated antigens. 10-35% 
* This work was supported by U.S.  Public Health Service grant GM 15253; by Contract 
National Institutes of Health NCI-E-69-2005 within the Special Virus Cancer Program of 
the National Cancer Institute, National Institutes of Health, U.S. Public Health Service; by a 
grant from the Swedish Cancer Society; and by the Cancer Research Campaign. 
J; Present address: Royal Marsden Hospital, London S.W.3, England. 
1  Abbreviations used in this paper: BSS,  balanced salt solution; G-6-PD, glucose-6-phos- 
A  B  phate dehydrogenase; Gd  , A allele; Gd  , B allele; KCC, Kenya Cancer Council. 
THE  JOURNAL O~"  EXPERIMENTAL  MEDICINE  • VOLUME 138,  1973  89 90  MARKERS  OF  CELLULAR  ORIGIN  IN  BURKITT  LYMPHOMA 
of  blood lymphocytes from normal subjects bear immunoglobulins on  their surfaces 
(7-13). It is thought  that  these cells  are members  of  the  bone  marrow-derived  (B) 
subpopulation  of  lymphocytes,  whereas cells  without  such  surface immunoglobulin 
belong to  the thymus-dependent  (T)  subgroup  (14,  15).  Surface-associated  immuno- 
globulin  on  most  normal  B  cells  is  IgM.  Presumably  these  molecules  function as 
receptors  which  combine  with  antigens  in  immunologically  specific  reactions  (15). 
Membrane-bound immunoglobulin on a normal B  lymphocyte is restricted to one class, 
one light chain, one IgG subclass, and 1 Gm allotype even in Gm heterozygotes (16). 
The presence of cell surface-associated immunoglobulin can be used as a  marker of 
neoplastic  lymphoid  cells  (17,  18).  Cells  from  almost  every  patient  with  chronic 
lymphocytic leukemia bear immunoglobulin, usually IgM,  on their surface suggesting 
a  B  cell  origin for  this disease  (7-13,  18).  Moreover,  since a  single B  cell generally 
bears  only  one  class  of  immunoglobulin  on  its  surface  (16),  the  restriction  to  one 
class on the surface of chronic lymphocytic leukemia cells is compatible with a  clonal 
origin for that disease. This suggestion receives strong support from findings that the 
surface-associated light chains in a  given patient are of only one type, either kappa or 
lambda  (7,  8,  10,  12,  17-19),  and from  observations in a  patient with IgG-positive 
leukemia cell surfaces that the IgG was  restricted to  one subclass and 1 Gm  allotype 
(8). Since IgM has been found on cells from some Burkitt tumors (17, 20), we explored 
the possibility of using this system as a  marker  to complement the  G-6-PD  studies. 
Materials and Methods 
Preparation of Cell Suspensions.--Biopsy  specimens obtained in Nairobi from patients with 
histologically and cytologically confirmed Burkitt tumors were shipped immediately to Stock- 
holm in Eagle's medium on wet ice.  Immunoglobulin tests were always performed within 24 
h after surgery. Viable cell suspensions were prepared by mincing and shaking the tissue pieces 
in tissue culture medium as previously described (17). 
Cell Surface-Associated Ig.--Fluorescein-conjugated goat immunoglobulins against human 
IgM, IgA, IgG, K-chain, ~k-chain, and Fc-fragment of IgG were obtained from Hyland Div., 
Travenol Laboratories Inc., Costa Mesa, Calif. Conjugated rabbit antilight chain reagent was a 
gift from Dr. G. Goldsteln (University of Virginia). The anti-IgG reagent was found to react 
in the passive hemagglutination test with IgM-coated erythrocytes. Therefore reactivities ob- 
served with this serum are not included in this report. The anti-~k reagent used during a long 
period of this study was later found to be inactive. Consequently, for the majority of the biop- 
sies no information about the presence of lambda on the cell surface is available. The reagents 
were used in 1:10 or 1:15, 1:20 or 1:25, and often in 1:40 dilutions. Anti-IgM was further di- 
luted serially to 1:640. 
Approximately 5  X  10 a cells were centrifuged in small tubes and 0.03 ml of diluted anti- 
immunoglobulin (anti-Ig) conjugated to fluorescein isothiocyanate was added to the sediment. 
The mixtures were incubated for 30 min at 37°C and the cells were then washed three times with 
balanced salt solution (BSS). One drop of 50% glycerol in BSS was added to the cells as a pre- 
.servative. 
A drop of the suspended cells was placed on a slide under a coverslip and 50-100 cells were 
,scored  for surface staining with a  fluorescent microscope. Cells with the diffuse  fluorescence 
typical of dead cells were disregarded. All cells showing sectorial or any degree of bright green 
granular fluorescence were counted as positive, even if they had only a few fluorescent spots on 
their surfaces. In scoring cell suspensions for surface fluorescence, the number of positive cells 
and the strength of the fluorescent  staining were  considered.  Therefore,  in  evaluating the 
staining results consideration was given not only to the percent of positive cells, but also to the ~IALKOW~  KLEIN~  KLEIN~  CLI~FORD~  AND  SINGI-I  91 
strength and pattern of the staining. The latter was assessed in two ways: one, at low  dilutions 
of anti-Ig sera, by scoring the reactions as weak, moderate, or strong; and, two, by testing dilu- 
tions of anti-Ig reagents. Reactions judged to be weak at low dilutions were almost always not 
present at high dilutions. In evaluation of surface IgM reactivity,  a  tumor was classified as 
positive (+) if at least 65% of cells were (+) at a dilution of 1 : 15 or 1 : 25 and at least 50% were 
(+)  at a  dilution of 1 : 160. 
G-6-PD Isoenzymes.--Blood, other normal tissues, and tumors were obtained, prepared, and 
the electrophoretic tuoe of G-6-PD determined as previously described  (4). In most instances 
each tumor biopsy specimen was divided into two parts. One part was used for G-6-PD typing 
and the other part was prepared for histological examination. A rough assessment was made of 
the relative proportion of tumor cells present and if this was less than 75%  of the total cells, 
the specimen was excluded. In many cases, tumor ceil suspensions were also typed for G-6-PD. 
RESULTS 
Surface-Associated IgM.--Only  results obtained on  the first studied  tumor 
from  each  patient  are  included  for  the  purposes  of  classifying  tumors  as 
IgM (+) or (--). The distribution of tumors according to the percent of IgM (+) 
cells is essentially bimodal (Fig. 1). In 58 of 95 patients 65 % or more cells were 
IgM(+)  at a  1:15 dilution of antiserum. There was excellent correlation be- 
tween the qualitative assessment of reactivity strength at low dilutions of anti- 
IgM reagent and the percent of cells which still remained (+) at higher dilutions. 
The frequency of IgM(+) cells at 1:160 dilution of antiserum declined to less 
than 50% in only one tumor scored as (+) at 1:15 or 1:25 dilution. Thus, 57 of 
95 (60 %) tumors were classified as IgM(+) and 40 % as IgM(-). 
The majority of IgM(--) tumors had 20% or less IgM(+) cells (Fig. 1), but 
there were three tumors with 30-35%  IgM(+)  cells and four with  50-60% 
IgM(+) cells. In all of the former, and, in one of the latter tumors the preva- 
lence of positive cells  declined rapidly with increasing dilutions of antiserum 
indicating weak reactivity. However, three tumors had 50-60% IgM(+) cells 
at low dilution of antiserum and retained those percentages of positive cells at 
1 : 160 dilution (Table I). Cells from the jaw tumor of patient 1,076 were nega- 
tive for surface Ig, but approximately 50 % of the cells in the suspension from 
t5- 
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TABLE I 
Surface-Associated  Immunoglobulin  on  Cells  from  Three  Burkitt  Tumors  Initially  Scored 
as" IgM(1) 
Test antiserum 
Specificity 
Percent of cells positive in tumor cell suspension 
KCC* 1,076 
Dilution  KCC 1,213  KCC 1,364 
Jaw:~  Ovary 
IgA 
Fc 
IgM 
K-chain 
Light chain 
1:15  0  0  6  20§ 
1:10  12  16  38  20 
1:15  14  NS][  58  57¶ 
1:25  0  47**  NS  50¶ 
1:40  NS  61"*  NS  58¶ 
1 : 160  NS  39**  48  58¶ 
1:320  NS  38  NS  60¶ 
1:640  NS  16  56  15 
1 : 15  5  62**  68  10 
1:15  2  52**  NS  NS 
* KCC, Kenya Cancer Council. 
This tumor was studied a second time with 
§ Very weak fluorescent staining. 
I] NS, not studied. 
similar results. 
¶ Great variation in staining pattern; sectorial and dotted fluorescence. 
** Strong sectorial reactivity. 
the ovarian tumor were positive for kappa as well as IgM. It should be empha- 
sized  that  the  surfaces  of  these  cells  showed  strong,  sectorial,  brilliant 
fluorescence.  Thus,  the cell suspension  from this  tumor clearly contained  two 
populations  of cells; one, negative for surface-Ig and  the  other strongly IgM 
and K-positive. 
Results from the other two tumors summarized in Table I  are more difficult 
to interpret. Surfaces of cells from patient 1,213's tumor reacted with nIost of the 
Ig reagents but in all instances the staining was not strong. Furthermore,  25 % 
of the cells in  this  suspension  were not viable indicating  that the preparation 
and test conditions were not optimal. Consequently, it is not possible to classify 
accurately this tumor as IgM(+)  or (-).  Cells in the tumor preparation from 
patient  1,364 exhibited unusually marked variability in staining  both quanti- 
tatively and qualitatively  (e.g., some cells showed sectorial and others,  dotted 
surface fluorescent patterns).  Since the expression of surface IgM is dependent 
on the cell's physiologic status (21), variable condition of the cells in this prepa- 
ration  could be responsible  for the  variability  in staining.  Consequently,  this 
tumor could not be classified accurately as IgM(+)  or (--). 
Studies of serially biopsied tumors showed that IgM(+)  tumors remain IgM 
(+)  (Fig. 2). For example, patient J. W.'s tumor was studied 13 times in 22 wk 
and  each time between  90 and  100%  of cells were IgM(+).  Tumors initially 
scored  as  IgM(--)  remained  IgM(--)  (Fig.  2).  In vitro,  lymphoblastoid  cell FIALKOW,  KLEIN~  KLEIN,  CLIFFORD,  AND  SINGH  93 
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FIG. 2.  Percent of cells with surface-associated IgM in serial biopsies of Burkitt tumors. 
lines derived from IgM(--) tumors are IgM(--), and cultures established from 
IgM(+)  tumors maintain the marker continuously in culture.  For example, a 
line derived from an IgM(+) tumor in the patient Daudi is still IgM(+) after 5 
yr  (20).  [On one occasion the line was thought to have become IgM(--)  (19), 
but subsequently it was shown that the culture was contaminated. The original 
line was recovered from the freezer, and still remains IgM (+).] 
Surface-Associated Light Chains.--Only two of 38 IgM(--) tumors scored as 
K(+). Approximately 40% of the IgM(+) tumors were classified as K(+), and 
the remainder as K(--). Data for five representative K(+) and five K(--) tumors 
are given in Table II. In all K(+) tumors the pattern of reactivity seen for K  was 
very similar to that observed for IgM. Thus, in the five K(+) tumors described 
in Table II, IgM and K-reactivities both were strong and sectorial. In the other 
five tumors, even those few cells recorded as K(+) had on their surfaces only a 
few fluorescent dots. This pattern was also seen for the cells recorded as (+) 
with the other Ig reagents with the exception of anti-IgM. 
As in the case of IgM, serial biopsies showed that K(+) tumors remain K(+). 
Thus, patient J. W.'s tumor, studied 13 times in 22 wk (Fig. 2), remained con- 
sistently K(+). Similarly, in vitro, lymphoblastoid cell lines derived from K(+) 
tumors maintain  that  marker. The Daudi  line  referred  to previously is  still 
K(+) after 5 yr (20). 
Other Surface-Associated Ig's.--None of the tumors was IgA(+). Only a few 
tumors had cells whose surfaces showed unequivocal reactivity with the reagents 
detecting IgG. Cells in lymphoblastoid lines established from two such tumors 
maintained surface-associated IgG reactivity thereby confirming the existence 
of IgG(+) Burkitt tumors. 
G-6-PD.--Since the previously reported results on 24 tumors from 12 G-6-PD 
heterozygotes (4, 5), we have studied 11 more tumors from 7 heterozygotes. One 
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TABLE  II 
Call-Surface  1,4 Reaclivilies  in Cell Suspensions  from Five Burkit!  Tumors Scored as IgM(+), 
(+) and Five as IgM(+),  n (--) 
Test antiserum  Percent of cells positive in tumor cell suspensions 
Specificity  Dilution  1,383"  786  19, 17i  1,375  1,397  1,202  1,080  1,367  1,229  1,223 
IgA$  1:15  16  26  0  67  50  7  0  0  12  28 
Fc~  1:10  48  NS§  NS  50  60  45  0  5  12  36 
IgM[[  1:15  70  100  94  100  100  80  84  81  80  81 
g[I  1:10  80  100  83  100  95  19  0  0  3  0 
* Kenya Cancer Council  (KCC)  patient number  except 19,171 which  is patient's unit 
number. 
In all cases reactivity with these reagents was weak and consisted of only a few dots. 
Therefore,  none of the cases is considered IgA or Fc(+). 
§ NS, not studied. 
I] In all cases IgM reactivity was strong and sectoria] and more  than 50% of cells were 
IgM(+) at 1 : 160 dilution of antiserum. K-reactivity was strong and sectorial in the first five 
cases. 
tumor cells. Single enzyme types (A or B) were found in 9 of the other 10 tumors. 
One  patient's only tumor  had  approximately equal  amounts  of A  and  B  en- 
zymes in specimens judged  to  contain  at least  75 %  tumor  cells and  in a  cell 
suspension prepared from the tumor. All ceils in  the  latter were  strongly IgM 
(+)  and K(-t-) with sectorial staining. Attempts to establish cell lines from this 
tumor failed. Combined with our previous reports (4, 5), these data show that 
33 of 34 tumors from  19 G-6-PD heterozygotes had single enzyme phenotypes 
(A or B)  despite the  fact  that  normal  tissues  (including blood lymphocytes) 
always had both A and B  typesof G-6-PD. Tumors from 11 heterozygotestyped 
as B, from 7 as A, and from 1 patient as AB. 
_Patients with Multiple Studied  Tumors.--In  17 patients, two or more tumors 
that were present simultaneously on initial presentation were studied for G-6- 
P-I) and/or surface-associated Ig (Table III). G-6-PD was determined in each 
of two tumors from seven heteroxygotes and in all seven instances both tumors 
had a single enzyme of the same electrophoretic type. The probability that this 
occurred by chance alone is less than  1%.  Surface-associated IglVI and  K were 
tested in four tumors from one patient, three tumors from another patient, and 
in two tumors from  11 patients. With one exception (case 1,076, Tables I  and 
III), multiple tumors from the same patient were either all IgM(+)  or IgM(--) 
and were  also concordant for K. The maxillary tumor from patient  1,076  con- 
sisted entirely of IgM(--),  K(--) cells, but  the  ovarian  tumor  contained  ap- 
proximately 50% IgM(+),  K(+) cells (Table I). As noted above, this tumor was 
classified as consisting of two cell populations [IgM(--) and IgM(+)]. 
Recurrent  Tumors.--A  tumor was considered to be recurrent rather than per- 
sistent if it was noted after what was judged clinically to be a  tumor-free inter- 
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ciated Ig and in 31  instances the phenotypes were concordant for IgM and K 
with those found in the initially studied tumors. Data from the two remaining 
recurrent tumors require detailed comment as the phenotypes seemed discordant 
with those observed in the initial tumors (Table IV). 
On initial presentation, patient 953 had ovarian and right maxillary tumors. 
Only the former was studied and it was classified as IgM(--), K(--). A complete 
remission was induced, but 6 mo after institution of therapy the maxillary tu- 
more recurred and typed as IgM(+), K(+). A remission was induced but once 
again  the maxillary tumor recurred  6 mo later.  This  tumor was classified  as 
IgM(-), K(--). Thus, the first and third studied tumors were concordant, but 
each was discordant with the second neoplasm. Unfortunately, this patient was 
not a  G-6-PD heterozygote. 
The initial maxillary tumor from patient 1,260 was clearly IgM(-- ), K(-- ). A 
sustained complete remissionwas induced, but 1~ yr after institution of therapy, 
tumor recurred in the right neck. Cells from this neoplasm were obtained by a 
needle biopsy and were sufficient in number to allow only limited testing. The 
cells reacted  strongly with  anti-IgM reagent  at  low  dilution.  Unfortunately, 
there was insufficient material to test a  1:160 dilution or with anti-K reagent. 
Eight recurrent tumors from G-6-PD heterozygotes were typed for the en- 
zyme. Five of these were also tested for IgM. The one case in which the G-6-PD 
phenotypes in an initial  and  a  recurrent  tumor were discordant has been re- 
ported previously (6). The IgM phenotypes in these tumors were concordant 
[IgM(+), K(+)]. 
In summary, 36 recurrent tumors from 29 patients were typed for membrane- 
associated IgM and/or G-6-PD isozymes in heterozygotes. Initial and recurrent 
tumors were discordant for G-6-PD in one patient and in two other cases, prob- 
ably were discordant for surface-associated Ig. 
The duration  of remission was defined as the interval  between the  time of 
initial therapy and the first observation of recurrent disease. All  tumors which 
recurred before 4 mo were located at previously involved anatomic sites. From 4 
mo onward,  10  of 20  recurrences  were  at  sites not previously involved with 
tumors. 
DISCUSSION 
In  approximately 60%  of Burkitt  tumors,  most of the  cells have surface- 
associated IgM. Some of the IgM(+) tumors are ~(+) and others are K(--) (e.g., 
Table II). Since cultured cells from these tumors may retain their surface-asso- 
ciated IgM indefinitely (20), it is produced by the cell bearing it. That the pres- 
ence or absence of surface-associated IgM reactivity is a specific characteristic 
of each tumor is indicated by the consistent findings in vitro and in vivo (Fig. 
2).  These observations indicate that membrane-bound IgM is a  good marker 
for Burkitt cells, permitting a consideration of several questions about the dis- 
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TABLE  III 
G-6-PD Isoenzymes  and  Cell Surface-Associated  IgM  Phenotypes  in Multiple  Tumors from 
Burkitt Patients Studied  on Initial Presentation 
Patient  Phenotypes 
Biopsy site 
KCC* no.  Sex  IgM  + 
G-6-PD 
Normal tissues  Biopsy 
1,054  F  R. eye  +  AB 
L.  mandible  + 
L. neck, anterior  + 
L. neck, posterior  + 
788  M  R. submandibular 
R. maxilla 
L. submandibular 
NS 
B 
NS§ 
NS 
NS 
NS 
NS 
NS 
899  M  Orbit  --  NS 
Maxilla 
NS 
NS 
1,076  F  Ovary  =i=  B 
R. maxilla 
B 
B 
1,106  F  Ovary  --  A-B 
L. mandible 
B 
B 
1,140  F  R. ovary  +  A 
R. maxilla  + 
A 
A 
1,143  F  R. ovary  +  A-B 
L. maxilla  NS 
1,165  F  L. ovary  --  B 
Omentum 
1,202  M  L. maxilla  +  B 
Submandibular  + 
1,225 
1,230 
1,260 
F  Breast  +  A-B 
L.  maxilla  + 
F  L.  orbit  NS  AB 
L. ovary  + 
F  R.  maxilla  --  AB 
R. neck 
A 
A 
A 
A 
1,305  F  L. maxilla  NS  A-B  B 
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TABLE III--Contlnued 
Patient  Phenotypes 
Biopsy site  G-6*PD 
KCC* no.  Sex  IgM* 
Normal tissues  Biopsy 
1,334  F  R. maxilla  --  A  A 
R. submandibular  --  A 
19,171  F  Omentum  +  AB  A 
Abdominal wall  NS  A 
43,955  F  L. maxilla  +  B  B 
L. submandibular  +  B 
45,230  M  R. maxilla  +  B  B 
L. mandible  +  B 
* KCC no., Kenya Cancer Council number except for last three patients whose unit num- 
bers are given. 
:~ IgM, Cell surface-associated IgM. See text for criteria used to score tumors as +  or --. 
§ NS, not studied. 
TABLE  IV 
Surface-Associated Ig on Tumor Calls from Two Burkitt Patients in Whom Initial and Recurrent 
Tumors were Found to be Discordant for IgM 
Test antiserum 
Specificity  Dilution 
Percent of cells positive in tumor suspensions 
KCC* 953  KCC 1,260 
Ovary  Maxilla  Maxilla  Mandible  Mandible* 
10/7/68  2/17/69  9/15/69  12/14/70  5/12/72 
Fc  1:10  NS§  NS  45  0  0 
IgM  1:15  31  86  36  5  100 
K  1:15  23  72  12  8  NS 
Light chain  1:15  4  71  NS  NS  NS 
* KCC, Kenya Cancer Council. 
2~ Puncture biopsy. 
§ NS, not studied. 
One question is whether Burkitt lymphoma affects T  or B  lymphoid ceils. 
Presumably, all lymphocytes in man are derived from a common marrow stem 
cell pool.  Differentiated lymphocytes are  currently separated  into two  main 
classes, B and T. B cells, thought to be the equivalent of bursal-dependent ceils 
in the chicken, synthesize and secrete antibodies. T  ceils are involved in "cell- 
mediated" immunity and they may also cooperate with or  "help"  B  cells to 
produce certain  types of antibodies. One of the characteristics distinguishing 
normal cells is the presence of easily detected surface-associated immunoglobu- 
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to neoplastic lymphocytes in attempts to classify malignant diseases into T  or B 
cell origin according to the presence or absence of surface-associated immuno- 
globulins. By this reasoning, at least half of Burkitt tumors are of B cell origin. 
However, recently it has been reported that T  cells may also have membrane- 
associated immunoglobulins although they are less  exposed than on the sur- 
faces of B cells (22). Since it is conceivable that malignant transformation of a 
T  or B cell may change its surface exposure of IgM, one cannot exclude T  cell 
origin of IgM(+) Burkitt tumors or B cell origin of IgM(-)  tumors. 
Studies in  G-6-PD  heterozygotes of 24 Burkitt tumors without significant 
"contamination" by normal  cells have been reported previously  (4,  5).  The 
combined data indicate that  33  of 34 tumors had single enzyme phenotypes 
(A or B) despite the fact that normal tissues had both A and B enzymes. The 
one tumor with equal amounts of A and B enzymes in a cell suspension and in 
tumor specimens that were judged to contain  .~  75 %  tumor cells may have 
had  multicellular  origin.  All  cells  in  this  tumor  were  IgM(+),~(+).  The 
most likely explanation for the single enzyme phenotypes found in the other 33 
tumors is that the majority of individual Burkitt tmnors have a clonal origin. 
However, an alternate possibility is  that  a  Burkitt tumor generally develops 
from many cells each of which has the same type of G-6-PD as the result of 
chance or of selection based on G-6-PD or based on phenotypes determined by 
loci linked to G-6-PD. That this is not the case is suggested by study of cell sur- 
face-associated IgM,  a  marker which is completely independent of  G-6-PD- 
phenotype. 
The distribution of Burkitt tumors with respect to the proportion of cells 
bearing surface IgM is essentially bimodal (Fig. 1). Thus, in 92 of 95 tumors, the 
cell population was either predominantly IgM (+) (60 % of tumors) or IgM (--). 
These findings are compatible with a clonal origin for the majority of Burkitt 
tumors. Two neoplasms could not be definitively classified.  One tumor (Kenya 
Cancer Council [KCC] 1,076, ovary tumor, Table I) probably contained two cell 
populations [IgM(+), K(+)  and  IgM(--), K(--)] possibly reflecting the  pres- 
ence of two or more malignant clones. Another neoplasm from this patient was 
IgM(--),K(--). However, it is conceivable that the cell suspensions prepared 
from the tumors were "contaminated" by normal cells.  Furthermore, the pres- 
ence of two clones would not necessarily imply multicelluar origin since it is 
conceivable that the second clone could have arisen from the first, for example, 
by marker loss. The likelihood of this possibility is somewhat decreased by the 
fact that IgM loss has not been observed on prolonged cultivation in vitro. 
The validity of the use of surface-associated IgM and K  as markers is suggested 
by the excellent correlations of these Ig's with G-6-PD phenotypes in multiple 
tumors from the same patient. In each heterozygous patient, multiple studied 
tumors were concordant for G-6-PD  (i.e., both tumors showed type A or both 
showed type B), and with one exception (case 1,076, Table III), they were con- 
cordant for IgM and for K. Apparently, in  most instances the disease emerges 
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The majority of patients with  Burkitt  lymphoma have therapeutically  in- 
duced "complete" remissions, but tumors reappear within 1 yr in about 60% of 
cases (23,  24). Previously we reported a G-6-PD heterozygote with a recurrent 
tumor that had an isoenzyme phenotype discordant with the one found in the 
patient's initial tumor (6). Thus, in this patient, exacerbation of disease did not 
result from reemergence of the originally detected malignant clone. Using sur- 
face-associated IgM as a marker, we detected one or possibly two patients in 
whom initial  and recurrent tumors were discordant for IgM phenotypes. Un- 
fortunately, in one case (1,260,  Table IV) the number of available cells from the 
recurrent tumor was too small to allow complete evaluation. Nonetheless,  the 
virtual absence of IgM(-]-) cells in the initial tumor and the presence of 100% 
strongly reactive IgM(q-) cells in the recurrence suggests that the tumors were 
truly discordant. The significance of the discordance found in the first recurrent 
tumor in the second case (953, Table IV) is somewhat confused by the fact that a 
second recurrence was concordant with the initial tumor. This might have been 
due to erroneous classification of the first recurrence, but it is possible that the 
malignant clone in this tumor was different from the one in the original neo- 
plasm and that the second recurrence resulted from yet another clone or from 
reemergence of the originally detected malignant cell line. 
Three of nine relapses which occurred after 5 mo were discordant with those 
found in initial tumors, but no discordance was detected among 27  earlier re- 
currences. Ziegler and associates (24)  suggest on the basis of clinical observa- 
tions, that the mechanisms underlying early and late recurrences may be differ- 
ent. Early relapses appear at previously involved anatomic sites whereas late 
regrowths often occur in previously uninvolved organs (24).  Furthermore,  the 
proportion of late relapses which have favorable therapeutic responses is similar 
to what is found in primary tumors. In contrast,  early relapses almost always 
have poor responses (24). Ziegler et al. therefore suggest that most early recur- 
rences are due to reemergence of the original malignant clones, while some late 
recurrences may be due to emergence of new malignant cell  lines. The genetic 
marker  (G-6-PD and surface-associated Ig) studies  indicate  that  early recur- 
rences are due to regrowth of the original tumor cell  line. One late recurrence 
was discordant for G-6-PD and two others probably were discordant for IgM 
possibly reflecting the emergence of new malignant cell lines. 
The two most likely origins for the new malignant clones are as follows: One, 
they could have arisen as reinductions of tumors in hitherto normal host cells. 
Two, they may have been present, but undetected when the patient was initially 
studied  because, for example, they did not grow sufficiently to form clinically 
evident tumors. Neither of these possibilities is incompatible with the suggestion 
that clinically detectable Burkitt lymphoma is generally a clonal disease on its 
first presentation. 
What implications does the probable clonal origin of Burkitt lymphoma have 
for the disease's putative viral  etiology? Although  viruses  infect  many cells, 
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G-6-PD  markers suggest  a  unicellular  origin  for the  one tumor in man  with 
proven viral etiology, Vermca z'ulgaris  (common wart)  (25). There are at least 
three circumstances in which a virally-induced neoplasm might have single cell 
origin. One, if the oncogenic change induced by the virus were relatively rare 
such as a specific somatic mutationqike event. Twol if lhe virus were a necessary 
but not a sufficient etiologic factor and one of the other tumorigenic co-factors 
affected only a single cell. Three, if many cells are altered by the virus, but once 
a malignant clone emerges, the growth of other clones is inhibited. In any event, 
since the disease is rare even in high endemic areas, the underlying biological 
"accident" must be a rare event. Is this a random phenomenon or do patients 
who develop Burkitt  lymphoma have an underlying  genetic  and/or  environ- 
mental predisposition? The suggestion that such patients "cured" of their origi- 
nal disease may sometimes have new occurrences of disease, is compatible with, 
but does not necessarily imply, the existence of predisposing factors. 
SUMMARY 
Two independent  marker systems, G-6-PD isoenzymes and cell membrane- 
associated IgM,  were used  to  trace the cellular origin  of Burkitt  lymphoma. 
Application of the G-6-PD system is dependent upon the fact that, in accordance 
with inactivity of one X  chromosome in each somatic cell, females heterozygous 
for the usual B  gene (Gd B) at the X-linked G-6-PD locus and the variant allele 
Gd  A (or Gd A-) have two types of cells. Gd  B is active in one cell population, which 
consequently produces B  type enzyme; in the other population Gd  ~  is active, 
producing the variant A  enzyme. Therefore, tumors with a  clonal origin in a 
GdB/Gd A heterozygote should exhibit only one enzyme type (B or A) whereas 
those with mnlticellular origin may show both A and B enzymes. Utilization of 
the immunoglobulin system is  based  upon  the  supposition  that  in  lymphoid 
neoplasms with clonal origin either all or none of the tumor ceils should have 
surface-associated IgM and K-reactivities. 
33 of 34 relatively homogeneous (with respect to content of neoplastic cells) 
individual  Burkitt  tumors from 19  G-6-PD heterozygotes had  single enzyme 
phenotypes. Similarly, of 95 tumors tested, 92 consisted essentially of IgM(+) 
or (--)  cells.  Two neoplasms could not be definitely classified and one tumor 
had two cell populations. These data suggest a  clonal origin for most Burkitt 
tumors, but the one neoplasm with a double G-6-PD phenotype (A/B) and the 
one tumor that had two populations of cells with respect to surface IgM, could 
have originated from multiple ceils. 
G-6-PD was determined in each of two tumors from seven heterozygotes and 
in all cases both tumors had the same single enzyme phenotype. Surface-asso- 
ciated IgM was tested in four tumors from one patient, three from another, and 
in  two neoplasms from 11  patients.  With  one exception,  all  tumors from the 
same patient were concordant with respect to IgM. These findings suggest that 
the  entire  disease has a  clonal  origin,  i.e.,  it emerges at  one  focus  and  then 
spreads to other parts of the body. ~'IALKOW, KLEIN,  KLEIN, CLI~F_PORD, AND  SINGH  101 
Cells from 36 recurrent neoplasms were typed for G-6-PD (in heterozygotes) 
and/or IgM. In one previously reported  patient,  initial  and recurrent  tumors 
were discordant for G-6-PD. Two other patients had IgM phenotypes in recur- 
rences that were discordant with those found in their initial tumors. Phenotypes 
from three of nine relapses which occurred after 5 mo were discordant for G-6- 
PD or IgM but no discordance was detected among 27 earlier recurrences. Thus, 
some  "late"  recurrences  may be  due  to  emergence  of  "new"  maligant  cell 
lines whereas most early relapses are due to reemergence of the original malig- 
nant clones. 
The  probable  unicellular  origin  of  Burkitt  lymphoma and  the  findings  in 
tumor recurrences are discussed in terms of the disease's putative viral etiology. 
We thank Mr. G. Herner, Mrs. Britt Marie Akerman, and Mrs. Ingegerd Carlsson for their 
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